Journal: Biomolecules

Article Title: Epitope-Specific Anti-SerpinB3 Antibodies for SerpinB3 Recognition and Biological Activity Inhibition

doi: 10.3390/biom13050739

Figure Lengend Snippet: Steric position of SerpinB3 epitopes. Steric position of SerpinB3-exposed epitopes (colored regions) chosen for antibody generation. Each peptide was prepared by solid-phase peptide synthesis method using a multiple peptide synthesizer (Syro II, Biotage, Uppsala, Sweden) on p -benzyloxybenzyl alcohol resin (Wang resin).

Article Snippet: They were prepared by solid-phase peptide synthesis using a multiple peptide synthesizer (Syro II, Biotage) on p -benzyloxybenzyl alcohol resins (Wang resin) or 2-chlorotrityl chloride resin for the synthesis of peptide #5, loaded with their C-terminal amino acids (Novabiochem, Bad Soden, Germany).

Techniques:

Journal: Frontiers in Molecular Biosciences

Article Title: Branched oncolytic peptides target HSPGs, inhibit metastasis, and trigger the release of molecular determinants of immunogenic cell death in pancreatic cancer

doi: 10.3389/fmolb.2024.1429163

Figure Lengend Snippet: Stability of the tetrabranched peptides to proteolysis. (A, C, E, G) HPLC profiles of the serum with spikes of the peptides, BOP7, BOP9, L7, and L9 monitored after 4 and 16 h of incubation; (B, D, F, H) MALDI-TOF mass spectrometry confirming the presence or absence of the intact peptides.

Article Snippet: Linear peptides L7 and L9 and branched oncolytic peptides BOP7 and BOP9 were synthesized on solid-phase by standard Fmoc chemistry on a Syro multiple-peptide synthesizer (MultiSynTech, Witten, Germany).

Techniques: Incubation, Mass Spectrometry

Journal: Frontiers in Molecular Biosciences

Article Title: Branched oncolytic peptides target HSPGs, inhibit metastasis, and trigger the release of molecular determinants of immunogenic cell death in pancreatic cancer

doi: 10.3389/fmolb.2024.1429163

Figure Lengend Snippet: (A, B) Flow cytometry analysis of: pancreatic cancer cells, PANC-1 and Mia PaCa-2; (C, D) cells of non-cancer origin, RAW 264.7, murine macrophages and pgsA-745 chinese hamster ovary cell mutant deficient in xylosyltransferase. (E) Quantification of fluorescence intensity of cells treated with 10 μM BOPs, each repeated value (n = 2) was averaged and divided by the value of the untreated cells; (F) ELISA of binding of BOPs to biotinylated heparin; *** p < 0.0001 (n = 6), one-way ANOVA and Dunnet post-test. (G, H) Flow cytometry analysis of BOP7 and BOP9 binding to PANC-1 and Mia PaCa-2 cells in the presence of 20 or 5 μg/mL heparin. On the right side of each graph, the quantification of fluorescence intensity, as % of BOPs binding (n = 2).

Article Snippet: Linear peptides L7 and L9 and branched oncolytic peptides BOP7 and BOP9 were synthesized on solid-phase by standard Fmoc chemistry on a Syro multiple-peptide synthesizer (MultiSynTech, Witten, Germany).

Techniques: Flow Cytometry, Mutagenesis, Fluorescence, Enzyme-linked Immunosorbent Assay, Binding Assay

Journal: Frontiers in Molecular Biosciences

Article Title: Branched oncolytic peptides target HSPGs, inhibit metastasis, and trigger the release of molecular determinants of immunogenic cell death in pancreatic cancer

doi: 10.3389/fmolb.2024.1429163

Figure Lengend Snippet: (A) Viability of PANC-1 cell line after BOP7 treatment. BOP7 IC50: 1.67 × 10 −6 M (n = 6) and BOP9 IC50: 8.3 × 10 −6 M (n = 11); (B) Viability of Mia PaCa-2 cell line. BOP7 IC50: 2.73 × 10 −5 M (n = 5) and BOP9 IC50: 1.78 × 10 −5 M (n = 5). (C) Viability of PANC-1 and (D) Mia PaCa-2 after treatment with L7 and L9; (E, F) Hemolytic activity of BOP7 and BOP9 (n = 3). Data in (A–E) were analysed with one way ANOVA, Dunnet post test ( *** p < 0.0001, ** p < 0.01, * p < 0.05). IC50 were calculated in a non-linear fit with log (inhibitor) vs. normalized response variable slope. All graphs are obtained with GraphPad Prism 5.

Article Snippet: Linear peptides L7 and L9 and branched oncolytic peptides BOP7 and BOP9 were synthesized on solid-phase by standard Fmoc chemistry on a Syro multiple-peptide synthesizer (MultiSynTech, Witten, Germany).

Techniques: Activity Assay